Abstract

Polatuzumab vedotin is a CD79b targeted antibody-drug conjugate that preferentially delivers a potent anti-mitotic agent to B cells. Expected benefits, in combination with bendamustine and rituximab (BR), are its ability to elicit higher rates of complete responses vs BR.